NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Pyxus International, Inc. (“Pyxus” or “the Company”) (NYSE: PYX) of the August 6, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Pyxus stock or options between June 7, 2018 and November 8, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/PYX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Eastern District of North Carolina on behalf of all those who purchased Pyxus securities between June 7, 2018 and November 8, 2018 (the “Class Period”). The case, Jones v. Pyxus International, Inc., No. 19-cv-00234 was filed on June 7, 2019 and has been assigned to Judge Terrence William Boyle.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose to investors: (1) that the Company was experiencing longer shipping

cycles; (2) that, as a result, the Company’s financial results would be materially affected; (3) that the Company lacked adequate internal control over financial reporting; (4) that the Company’s accounting policies were reasonably likely to lead to regulatory scrutiny; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On November 8, 2018, the Company disclosed that sales declined approximately 12% year-over-year due to the timing of shipments and the larger crop last year in South America.

On this news, the Company’s stock price fell from $25.27 on November 7, 2018 to $18.26 on November 8, 2019- a $7.01 or 27.74% drop.

Then, on November 9, 2018, the SEC announced that the Company had settled charges that it had materially misstated financial statements with the Commission from at least 2011 through the second quarter of 2015 due to improper and insufficient accounting, processes, and control activities for inventory, deferred crop costs, and revenue transactions in Africa. 6.

On this news, the Company’s stock price fell from $18.16 on November 8, 2018 to $15.38 on November 9, 2019- a $2.88 or 15.77% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Pyxus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 553520

BALA CYNWYD, PA / ACCESSWIRE / July 26, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Monotype Holdings Inc. (“Monotype” or “the Company”) (NYSE: TYPE News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to private equity firm HGGC (“HGGC”).

Click here to learn more http://www.brodskysmith.com/cases/monotype-holdings-inc-nasdaq-type/, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Monotype shareholders will receive only $19.85 in cash for each share of Monotype stock they own. The investigation concerns whether the Board of Monotype breached their fiduciary duties to shareholders and whether HGGC is underpaying for the Company. The transaction may undervalue the Company and would result in a loss for many Monotype shareholders. For example, Monotype stock has traded at $32.64 per share and an analyst has set a $23.00 per share price target for the stock.

If you purchased shares of Monotype stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004 by calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 553588

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zuora, Inc. (“Zuora” or the “Company”) (NYSE:ZUO) of the August 13, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Zuora stock or options between April 12, 2018 and May 30, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/ZUO. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Zuora securities between April 12, 2018 and May 30, 2019 (the “Class Period”). The case, Roberts v. Zuora, Inc., No. 3:19-cv-03422 was filed on June 14, 2019.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making materially false and/or misleading statements, as well as failing to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, Defendants failed to disclose to investors: (1) that the Company would focus on implementing RevPro for new customers ahead of the deadline to comply with accounting standard ASC 606; (2) that, as a result, the Company lacked adequate resources to integrate RevPro with the core business; (3) that the Company would focus on RevPro integration a year after the acquisition closed; (4) that delays in integrating RevPro would materially impact the business; (5) that the market for RevPro was limited to customers seeking to implement new accounting standards such as ASC 606; (6) that, after the deadline for ASC 606 compliance passed, demand for RevPro was reasonably likely to decline; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On May 30, 2019, the Company lowered its fiscal 2020 revenue guidance to a range of $268 million to $278 million, from prior guidance of $289 million to $293.5 million, citing problems integrating RevPro, as well as sales execution problems.

On this news, the Company’s stock price fell from $19.90 per share on May 30, 2019 to $13.99 per share on May 31, 2019- a $5.91 or 29.70% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Zuora’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 553522

RADNOR, PA / ACCESSWIRE / July 26, 2019 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Eros International plc (NYSE: EROS) (“Eros”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Eros publicly traded securities between July 28, 2017 and June 5, 2019, inclusive (the “Class Period”).

Important Deadline Reminder: Investors who purchased Eros securities during the Class Period may, no later than August 20, 2019, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please visit www.ktmc.com/eros-international-plc-securities-class-action.

According to the complaint, Eros is a leading company in the Indian film entertainment industry and co-produces, acquires and distributes Indian language films in multiple formats worldwide.

The Class Period commences on July 28, 2017, when Eros issued a press release containing its financial results for the fiscal year 2017, ended March 31, 2017.

The complaint alleges that, on June 5, 2019, CARE Ratings, India’s second largest credit ratings agency, downgraded the credit rating for Eros’s Indian subsidiary, Eros International Media Ltd (“EIML”), to “Default” because of “ongoing delays/default in debt servicing due to slowdown in collection from debtors.” Then, on June 6, 2019, Eros issued a press release admitting that EIML was late on two loan interest payments for April and May 2019. Following this news, shares of Eros fell $3.59 or over 49% to close at $3.71 per share on June 6, 2019.

The following day, Hindenburg Research published an article entitled “Eros International: On-The-Ground Research, Employee Interviews, and Private Company Documents Expose Egregious Accounting Irregularities,” explaining the reason for the downgrade of EIML. The article stated, among other things, that “a significant portion of Eros’s receivables don’t exist” and that they have documented “multiple undisclosed related-party transactions that appear designed to hide receivables.”

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party transactions to fabricate receivables that they reported in Eros’s public financial disclosures; (2) because of this scheme, Eros’s financial position was weaker than what Eros disclosed; (3) consequently, EIML missed loan payments and had its credit downgraded; and (4) due to the foregoing, the defendants’ statements about Eros’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to discuss this securities fraud class action lawsuit or have any questions concerning this notice or your rights or interests with respect to this litigation, please contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 887-9500 (toll free) or (610) 667-7706, or via e-mail at info@ktmc.com.

Eros investors may, no later than August 20, 2019, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 553505

RADNOR, PA / ACCESSWIRE / July 26, 2019 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Pivotal Software, Inc. (NYSE: PVTL) (“Pivotal”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Pivotal common stock between 1) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Pivotal’s April 2018 initial public offering (“IPO”); and/or 2) between April 24, 2018 and June 4, 2019, inclusive (the “Class Period”).

Important Deadline Reminder: Investors who purchased Pivotal securities during the Class Period may, no later than August 19, 2019, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please visit www.ktmc.com/pivotal-software-inc-securities-class-action.

According to the complaint, Pivotal, together with its subsidiaries, provides a cloud-native application platform and services in the United States. Pivotal’s cloud-native platform, Pivotal Cloud Foundry (“PCF”), purportedly accelerates and streamlines software development by reducing the complexity of building, deploying, and operating cloud-native and modern applications. Pivotal also purportedly enables its customers to accelerate their adoption of a modern software development process and their business success using its platform through its strategic services, Pivotal Labs (“Labs”). Pivotal markets and sells PCF and Labs through its sales force and ecosystem partners.

In April 2018, Pivotal commenced the IPO, issuing over 42 million shares of Pivotal common stock to the investing public at $15.00 per share, all pursuant to the Registration Statement, raising more than $638 million in gross proceeds.

According to the complaint, on June 4, 2019, post-market, Pivotal reported its financial and operating results for the first quarter of fiscal year 2020, advising investors that “sales execution and a complex technology landscape impacted the quarter.” Wedbush Securities analyst Daniel Ives called the quarter a “train wreck” and characterized Pivotal’s operating results as “disastrous,” asserting that Pivotal’s “management team does not have a handle on the underlying issues negatively impacting its sales cycles and the activity in the field which gives us concern that this quarter will be the start of some ‘dark days ahead’ for Pivotal (and its investors).” Following this news, Pivotal’s stock price fell $7.65 per share, or over 40%, to close at $10.89 per share on June 5, 2019.

The complaint alleges that, in the Registration Statement and throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry’s sentiment shifted away from Pivotal’s principal products because Pivotal’s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, Pivotal’s public statements were materially false and misleading at all relevant times.

If you wish to discuss this securities fraud class action lawsuit or have any questions concerning this notice or your rights or interests with respect to this litigation, please contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 887-9500 (toll free) or (610) 667-7706, or via e-mail at info@ktmc.com.

Pivotal investors may, no later than August 19, 2019, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 553504

VANCOUVER, BC / ACCESSWIRE / Friday July 26, 2019 / Theramed Health Corporation (CSE: TMED, OTCQB: EVAHF) (the “Company”) is pleased to announce the ongoing standstill with its research operator for the medical system has been settled with a mutual termination, settlement and option to acquire 100% of the operator-developer. The parties agreed to a mutual release and cancelling $224,169 of accrued development fees that was payable from the Company. In addition, any business intelligence or know-how in relation to the medical health system that was under development would be made available to the Company. The Company also acquired an option to purchase the operator-developer for $1,000 in addition to 5% in cash payments for a ten year term, resulting from gross revenues generated by the systems or intellectual property of the operator.

UPDATE TO SPINOFF EVENT FOR EGF HEALTH HOLDINGS CORP.

The plan of arrangement as previously announced March 17, 2017, updated July 12, 2019, and July 19, 2019 of its wholly owned subsidiary “EGF HEALTH HOLDINGS CORP.” (“EGF”) as a spin out has been amended to be effective Friday July 26, 2019. EGF Health Holdings Corp.’s new CUSIP is 268470101 and its ISIN is CA2684701014. The plan of arrangement dated February 6, 2017 as voted on, received 100% shareholder approval and the Company received the final court order March 16, 2017. The share conversion exchange will be conducted at a 0.05 conversion rate as approved and voted on under the plan of arrangement circular.

THERAMED HEALTH CORPORATION

Email theramedhealthcorp@gmail.com

Website http://www.theramedhealthcorp.com http://www.evahealthsystems.com

CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news

About THERAMED HEALTH
(CSE: TMED, OTCQB: EVAHF)

Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/Theramed-Health-Corporation, and http://www.otcmarkets.com/stock/EVAHF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

SOURCE: Theramed Health Corporation

ReleaseID: 553676

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (NASDAQ: CCIH) of the August 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in ChinaCache stock or options between April 10, 2015 and May 17, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/CCIH. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017

Attn: Richard Gonnello, Esq.

rgonnello@faruqilaw.com

Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased ChinaCache securities between April 10, 2015 and May 17, 2019 (the “Class Period”). The case, Sun v. ChinaCache International Holdings Ltd. et al., No. 19-cv-05485 was filed on June 12, 2019, and has been assigned to Judge Edgardo Ramos

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) ChinaCache and former Chief Executive Officer (“CEO”) Song Wang were engaged in enterprise bribery; (2) the foregoing conduct placed ChinaCache and Wang at a heightened risk of criminal investigation and enforcement action by government authorities, which would foreseeably disrupt the Company’s operations; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Specifically, on May 17, 2019, ChinaCache announced that the Company and Wang were under criminal investigation by a government prosecutor office in Beijing for charges of enterprise bribery, and that Wang had resigned as CEO.

On this news, the Company’s stock price fell from $1.10 per share on May 16, 2019 to $0.88 per share on May 17, 2019: a $0.22 or 20.00% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding ChinaCache’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 553519

DENVER, CO / ACCESSWIRE / July 26, 2019 / International Cannabrands Inc. (CSE: JUJU) (the “Company”) wishes to announce that is has entered into a binding letter agreement with Sea Otter Global Ventures, LLC (“Sea Otter”) whereby Sea Otter has agreed to fund up to $6,250,000 by way of an ongoing share purchase commitment in tranches of $100,000 up to $250,000 over a period of 24 months. The Company has agreed to file a short form shelf prospectus in order to qualify the distribution of the securities issuable to Sea Otter, which will be priced in the context of the market and at discounts permitted under the rules of the Canadian Securities Exchange. The Company has issued a combination of common shares and warrants as consideration for providing the equity line of credit consisting of 3,500,000 common shares and 200,000 warrants. Each warrant entitles the holder to purchase one additional common share for a period of 2 years at a price of $0.072 per share. The common shares and warrants are subject to a four month hold period.

Steve Gormley commented: “Traditional operating lines are just not available to junior companies and particularly those in the cannabis space. This facility allows the Company to smooth out its cash flow and back stop its operations if needed, while we navigate our early design. We need to employ all the tools we can to ensure the success and growth of the Company, and we feel the team we have chosen in Sea Otter is first class.”

In addition, the Company wishes to report on private placements closed during the second quarter. The Company issued 5,079,365 common shares at a price of $0.07875, and an aggregate of 3,701,587 units at a price of $0.07875 for gross proceeds in the two placements of $691,500. Each unit consisted of one common share and one share purchase warrant, whereby each warrant entitles the holder to purchase one common share at a price of $0.13 for a period of three years. The issuance price of the securities was done at a discount to market at the time of the placement in accordance with the rules of the Canadian Securities Exchange. Two directors of the Company entered into share lending arrangements with certain of the investors, lending an aggregate of 8,253,968 common shares in connection with the private placements. The common shares and warrants bear a 4 month hold period. In addition an aggregate of 1,287,130 warrants with no hold period remaining were exercised for gross proceeds of $94,356.

The Company wishes to clarify disclosure in its press release dated August 9, 2018, relating to an investment agreement (the “Investment Agreement”) with Alumina Partners (Ontario) Ltd. (the “Investor”) dated August 8, 2018. The Company disclosed that “the draw downs are at the sole discretion of the Company.” The Investment Agreement contains provisions that the Investor does not have to close if the “closing price” as of the trading day prior to the date the securities are issued to the Investor is below the price at which the Company agreed to issue securities to the Investor. Under the Investment Agreement, all securities issued to the Investor are to be issued at the maximum discount allowable under the rules of the Canadian Securities Exchange. Accordingly, the draw downs are not at the “sole discretion” of the Company but are subject to this condition as well as to the following conditions: (a) the Company shall not be subject to a cease trade order; (b) the Company shall continue to be listed on the Exchange; (c) the Company shall confirm the representations and warranties contained in the Investment Agreement; (d) the Company shall not be in breach of any covenant in the Investment Agreement; and (e) no proceedings shall have been commenced for the liquidation, dissolution, bankruptcy, insolvency or winding-up of the Company or a substantial part of its business.

About International Cannabrands (ICI)

ICI’s strategy centers on acquiring micro brands, distribution and specific manufacturing/cultivation companies in the cannabis space. The Company’s business model is to generate revenue from cannabis cultivation, brands ranging from flower to edibles and from THC to CBD, oil extraction, ancillary products and apparel in the United States. ICI markets products with THC content where that practice has been legalized at the state level through either medicinal or full recreational use. ICI also markets products containing CBD in the US and internationally. ICI owns 51% of La Vide Verde, Inc. and has the exclusive rights to Julian Marley’s JuJu Royal™ brand. The Company believes as the legal cannabis market evolves, high-quality, unique products will increasingly capture market share and provide a valuable platform for growth.

International Cannabrands Contact:

Steve Gormley Chief Executive Officer 1045 Lincoln Street, #106 Denver, Colorado 80203 Ph: (323) 828-4321 or steve.gormley@intlcannabrands.com Media Inquiries: media@jujuroyal.net

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Disclaimer concerning Forward-looking Statements

Certain statements included herein constitute “forward-looking statements” relating to the obligations under the LOI, within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Investors are cautioned not to put undue reliance on forward-looking statements. Additional risks and uncertainties regarding the Company are described in its publicly-available disclosure documents filed by the Company on SEDAR (www.sedar.com). The forward-looking statements contained in this news release represent the Company’s expectations as of the date of this news release, or as of the date they are otherwise stated to be made, and subsequent events may cause these expectations to change. Except as required by law, the Company does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

SOURCE: International Cannabrands Inc.

ReleaseID: 553669

RADNOR, PA / ACCESSWIRE / July 26, 2019 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Zuora, Inc. (NYSE: ZUO) (“Zuora”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Zuora securities between April 12, 2018 and May 30, 2019, inclusive (the “Class Period”).

INVESTOR REMINDER: Investors who purchased Zuora securities during the Class Period may, no later than August 13, 2019, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please visit www.ktmc.com/zuora-inc-securities-class-action.

According to the complaint, Zuora is a cloud-based subscription management platform. Its business consists of three components: Zuora Central Platform, a subscription management hub; order-to-revenue products; and an application marketplace. Its flagship products are Zuora RevPro (“RevPro”), a revenue recognition automation solution that enables customers to group transactions into revenue contracts and performance obligations, and Zuora Billing (“Billing”), which is designed for subscription billing.

The Class Period commences on April 12, 2018, when Zuora filed its Initial Public Offering Prospectus.

According to the complaint, on May 30, 2019, in connection with its first quarter 2020 financial results, Zuora lowered its fiscal 2020 revenue guidance to a range of $268 million to $278 million, from prior guidance of $289 million to $293.5 million. Zuora reported that the product integration for Billing and RevPro “is taking longer than expected” and that “the technical work to complete the integration is taking time as these are complex mission-critical systems.” As a result of the product integration delay, Zuora slowed down RevPro implementations. Zuora also reported certain sales execution problems that slowed down its ability to cross-sell its products, which “resulted in lower professional services and subscription revenue in the quarter.” Following this news, Zuora’s share price fell $5.91 per share, nearly 30%, to close at $13.99 per share on May 31, 2019.

The complaint alleges that, throughout the Class Period, the defendants failed to disclose to investors that: (1) Zuora would focus on implementing RevPro for new customers ahead of the deadline to comply with accounting standard ASC 606; (2) as a result, Zuora lacked adequate resources to integrate RevPro with the core business; (3) Zuora would focus on RevPro integration a year after the acquisition closed; (4) delays in integrating RevPro would materially impact the business; (5) the market for RevPro was limited to customers seeking to implement new accounting standards such as ASC 606; (6) after the deadline for ASC 606 compliance passed, demand for RevPro was reasonably likely to decline; and (7) as a result of the foregoing, the defendants’ positive statements about Zuora’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Investors who wish to discuss this securities fraud class action lawsuit and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 887-9500 (toll free) or at info@ktmc.com.

Zuora investors may, no later than August 13, 2019, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 552492